ARCH-Vet

Report on the sale of antibiotics for veterinary use
and antibiotic resistance monitoring of livestock in Switzerland

Short version

2010

The full report is available online at
http://www.swissmedic.ch/archvet-d.asp
Publisher

Federal Veterinary Office (FVO)
Schwarzenburgstrasse 155
3003 Bern

Swissmedic, Swiss Agency for Therapeutic Products
Hallerstrasse 7
3000 Bern 9

Authors

Sabina Büttner
Federal Veterinary Office
Monitoring / Surveillance of Animal Diseases and Zoonoses
sabina.buettner@bvet.admin.ch

Olivier Flechtner
Swissmedic
Market Monitoring of Medicines
olivier.flechtner@swissmedic.ch

Cedric Müntener
Swissmedic
Safety of Medicines
cedric.muentener@swissmedic.ch

Gudrun Overesch
Center for Zoonoses, Bacterial Animal Diseases and Antibiotic Resistance (ZOBA)
University of Bern
Institute of Veterinary Bacteriology
gudrun.overesch@vetsuisse.unibe.ch
Contents

SUMMARY ........................................................................................................................................4

Use of antibiotics in veterinary medicine 4
Antibiotic resistance in livestock 4
In focus 6
Literature 8
**SUMMARY**

**Use of antibiotics in veterinary medicine**

Once again there has been a decrease in overall quantities: compared with the previous year, the quantity of active substances sold fell by 3.9%. In relation to the previous maximum of 2008, there has thus been a decline of 9.4% (6894 kg) in total quantities. This year, too, the ranking of antibiotics according to quantities sold remains unchanged. The substances that were sold the most were sulphonamides, followed by tetracyclines and penicillins. At 67.4%, medicated premixes (MPs) accounted for approximately the same proportion of total quantities in 2010 as in previous years.

In the case of products approved solely for use in pets, the quantity of fluoroquinolones sold rose 12% in 2010 and also compared with the previous year, having remained stable in the previous years.

The steady increase in cephalosporins, which was already observed last year, has also continued this year. This is especially noticeable with the products for the treatment of mastitis during lactation, for which 60% more cephalosporins were sold in 2010 than in 2006. Although cephalosporins only account for 1.6% of the quantities of all active ingredients sold in this product group, they account for 16% of all potential treatments.

**Antibiotic resistance in livestock**

In 2010 samples were taken from broilers, fattening pigs and calves in the slaughterhouse for resistance monitoring and then analysed in the Centre for Zoonoses, Bacterial Animal Diseases and Antibiotic Resistance (ZOBA).

**Table 1: Antibiotic resistance monitoring programme 2010**

<table>
<thead>
<tr>
<th>Type of sample</th>
<th>Number of samples</th>
<th>Bacteria tested</th>
<th>Number of resistance tests</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cloacal swab - broilers</td>
<td>398 (groups of 5)</td>
<td>Campylobacter spp.</td>
<td>126</td>
</tr>
<tr>
<td>Cloacal swab - broilers</td>
<td>200 (groups of 5)</td>
<td>E. coli</td>
<td>183</td>
</tr>
<tr>
<td>Cloacal swab - broilers</td>
<td>219 (groups of 5)</td>
<td>Enterococci</td>
<td>185</td>
</tr>
<tr>
<td>Cloacal swab - broilers</td>
<td>398 (groups of 5)</td>
<td>MRSA</td>
<td>0</td>
</tr>
<tr>
<td>Faecal swab - broilers</td>
<td>296</td>
<td>Campylobacter spp.</td>
<td>192</td>
</tr>
<tr>
<td>Faecal swab - broilers</td>
<td>201</td>
<td>E. coli</td>
<td>179</td>
</tr>
<tr>
<td>Faecal swab - broilers</td>
<td>381</td>
<td>Enterococci</td>
<td>138</td>
</tr>
<tr>
<td>Nasal swab - broilers</td>
<td>392</td>
<td>MRSA</td>
<td>23</td>
</tr>
<tr>
<td>Faecal swab - slaughter calves</td>
<td>245</td>
<td>Campylobacter spp.</td>
<td>37</td>
</tr>
<tr>
<td>Faecal swab - slaughter calves</td>
<td>204</td>
<td>E. coli</td>
<td>184</td>
</tr>
<tr>
<td>Faecal swab - slaughter calves</td>
<td>249</td>
<td>Enterococci</td>
<td>134</td>
</tr>
<tr>
<td>Nasal swab - slaughter calves</td>
<td>240</td>
<td>MRSA</td>
<td>5</td>
</tr>
<tr>
<td>Clinical material / all animal species</td>
<td>not applicable</td>
<td>Salmonella spp.</td>
<td>105</td>
</tr>
<tr>
<td>Clinical material / all animal species</td>
<td>not applicable</td>
<td>S. Typhimurium incl. monophasic variant</td>
<td>47</td>
</tr>
<tr>
<td>Clinical material / all animal species</td>
<td>not applicable</td>
<td>S. Enteritidis</td>
<td>14</td>
</tr>
</tbody>
</table>
Since *Salmonellae* only very rarely occur in Swiss livestock, this bacterial species was not included in the active monitoring programme. But all *Salmonellae* from clinical material sent to the ZOBA in its function as a reference laboratory underwent resistance testing. The relevant results for *Salmonellae* from birds, bovine animals and pigs have likewise been compiled in this report.

**Resistance in zoonotic agents from healthy animals**

In the case of *Campylobacter* spp., high rates of resistance to (fluoro)quinolones and to tetracycline were found in all three animal species tested. *C. coli* isolates from pigs and calves also showed resistance to streptomycin in an extremely high percentage. A comparison of the resistance situation of *C. jejuni* and *C. coli* from broilers over the last few years shows that resistance to these substances has increased. This is a worrying development, since fluoroquinolones are among the most important antibiotic classes both for veterinary and for human medicine.

In 23 of 392 nasal swabs from fattening pigs methicillin-resistant staphylococci (MRSA) were discovered. The occurrence of MRSA in fattening pigs in Switzerland has thus increased significantly from 2.2% to 5.9% compared with the previous year. Further molecular testing showed that the increase was due to a further spread of two clonal lines, one of which is a widespread line in Europe and the other a line specific to the Swiss swine population (Overesch, 2011). The prevalence of MRSA in calves was very low at 2.1%, while no MRSA-positive samples were discovered in broilers. Compared with other European countries, MRSA prevalence in Swiss livestock thus remains very low and the risk of transmission from animals to humans can be regarded as minimal. But the situation should continue to be monitored, especially in fattening pigs.

**Resistance in indicator bacteria from healthy animals**

Resistance in non-pathogenic *E. coli* from Swiss farm animals is widespread. Compared with previous years, the resistance situation has not significantly changed. High to very high rates of resistance to sulphamethoxazole, streptomycin, tetracycline and ampicillin have been observed. Sulphonamides, tetracyclines and penicillins are antibiotics that are often used in veterinary medicine. In broilers, resistance to fluoroquinolones was also often found. If broilers are treated for bacterial diseases, fluoroquinolones are used in more than 70% of cases (ARCH-Vet, 2009). For the first time, in the course of resistance monitoring, two *E. coli* from broilers were isolated that produce an extended-spectrum β-lactamase (ESBL) and are thus resistant to all penicillins and cephalosporins. Since this resistance could prove to be of major significance for human medicine, its occurrence must continue to be monitored in the future and molecular genetic studies must be conducted to explore more closely the correlation with ESBL resistance genes that have been found in humans.

Resistance has also often been observed in enterococci. Both *E. faecalis* and *E. faecium* from all three animal species showed very high to extremely high rates of resistance to neomycin and bacitracin. Rates of resistance to tetracycline were also very high in *E. faecalis* as was resistance to quinupristin/dalfopristin in *E. faecium*. Both bacterial species of all three animal species also showed high rates of resistance to erythromycin. No vancomycin-resistant enterococci were found in the year under review.

**Resistance in Salmonellae from clinical material**

As in the last few years, *S. Typhimurium* strains showed more resistance than *S. Enteritidis* strains. The high rates of resistance in *S. Typhimurium* compared with previous years are due to the fact that the monophasic strain 4,12:i:- is now also regarded as a *S. Typhimurium* strain and this strain often shows multi-resistance.
In focus

The joint publication of data on the sale of antibiotics in veterinary medicine and resistance to antibiotics in livestock allows a correlation of the values and trends that are observed. Yet conclusions are only possible to a limited extent, because statistics on the sale of antibiotics do not allow a precise estimate of the active substances that are actually used in the various animal species, and the development of resistance is assessed to some extent only on the basis of fewer isolates or over a short observation period. In the following some of the notable results from both reports are discussed jointly.

Development of resistance in zoonotic agents:

The resistance situation in zoonotic agents and indicator bacteria from Swiss livestock has not substantially changed for most antibiotics. However, there has been a slight increase in resistance to (fluoro)quinolones. Fluoroquinolones are considered important reserve antibiotics both in veterinary and in human medicine.

Last year also saw an increase in MRSA prevalence in the Swiss pig population (Overesch, 2011). These strains are resistant to all beta-lactam antibiotics and often also to several other active substance groups, for example tetracyclines. In humans, the MRSA strains that are important in veterinary medicine primarily play a role in people who work with farm animals. In this case, people may also act as MRSA carriers and facilitate a (re)infection of the animals. Antibiotic control strategies are often counterproductive in such situations, because these bacteria are often multiresistant. Good standards of hygiene must therefore be established and favoured, because the use of antibiotics can lead directly to a selection of resistant bacteria.

Cephalosporins and ESBL

Over the period 2006-2010, cephalosporins are the only group of substances that showed a steady increase. This is especially marked in the third and fourth-generation cephalosporins. Some substances in these groups have high Maximum Residue Levels (MRLs), which results in very short withdrawal periods, especially for the milk of treated cows. This plays an important part in the selection of a product (Pokludova, 2009). Third and fourth-generation cephalosporins are among the most important substance groups both in human and in veterinary medicine. Against this background, Collignon and Aarestup criticized the high level of permitted MRLs back in 2007. They voiced their suspicion that these products were being used instead of other substances because of their short withdrawal periods.

Cephalosporins belong to the beta-lactam antibiotics, and thus are involved in the selection of extended-spectrum beta-lactamases (ESBLs). While all beta-lactam antibiotics can exert a selection pressure, the potential is greater with newer-generation cephalosporins (Cavaco, 2008). The same authors also showed that the selection effect is preserved beyond the planned withdrawal period.

In the last few years, ESBL-producing bacteria have increasingly led to problems in human medicine. In Switzerland, ESBL-producing *E. coli* were detected for the first time in broilers during routine *E. coli* assays for resistance monitoring. A study in pigs and calves at slaughter also showed in selective assays that 15% and 17% of faecal samples contain ESBL-producing bacteria (Geser, 2011). Yet the prevalence of resistance is only of limited significance, because resistant strains or their mobile genetic elements can be transmitted to other individuals. The risk of selection thus increases if antibiotics are used. Horton et al. pointed out this situation in the case of ESBLs that were detected in livestock (Horton, 2011). While they detected low median values for the prevalence of ESBL-expressing *E. coli* in
bovine animals (0.013%), poultry (0.0197%) and pigs (0.121%) in their study, the authors pointed out at the same time that greater consideration has to be given to the absolute figures of ESBL-positive bacteria when evaluating the risk of resistance spreading.

The role of livestock as a reservoir for ESBL-producing bacteria has not yet been unequivocally clarified. A direct transmission of resistance from poultry to humans via meat was suspected, for example, in the Netherlands on the basis of genotyping of plasmids (Leverstein-van Hall, 2011). The horizontal transmission of ESBL genes between *E. coli* isolates of poultry and humans has been demonstrated *in vitro* in treatment with cefotaxim, a third-generation cephalosporin (Smet, 2010).

Since this resistance is of major significance in human medicine, this development must continue to be observed through both resistance monitoring and checks on the sale of antibiotics.

Cephalosporins are also increasingly being marketed in products for intramammary administration. This, too, marks the continuation of a trend over the last few years. As already mentioned in the last report (ARCH-Vet, 2009), no milk samples have so far been studied for resistance as part of the antibiotic resistance monitoring programme. The resistance situation with mastitis pathogens is also not routinely studied, so it is not known whether this development is associated with an increase in resistance among mastitis pathogens or other microorganisms that are not primarily pathogenic. In a study from Italy, however, 9 of 140 Klebsiella isolates from clinical cases of mastitis were resistant to ceftiofur (Locatelli, 2010). Only one of these isolates was unequivocally identified as a producer of ESBLs. A correlation between the use of newer (3rd and 4th) generation cephalosporins and the prevalence of ESBLs was demonstrated in a study from the Czech Republic (Dolejska, 2011). Once again it must be pointed out that a systematic monitoring of resistance development in bacteria isolated from milk is important in order to correlate this with the development of sales figures. In 2011, as part of a pilot study, the resistance situation will be analysed for the first time in selected microorganisms from tank milk.
Literature


Overesch G, Büttner S, Rossano A, Perreten V. The increase of methicillin-resistant Staphylococcus aureus (MRSA) and the presence of an unusual sequence type ST49 in slaughter pigs in Switzerland, 2011. BMC Veterinary Research (in press).
